随着新型卡比多巴/莱沃多巴功能评分片的更频繁使用,减少了血莱沃多巴的波动
Thomas N Chase1, Ahmad Al-Sabbagh2, Minako Koga1
1Riverside Pharmaceuticals, Washington, DC, USA.
Clinical pharmacology in drug development
|January 4, 2024
概括
新的嘉比多巴/莱沃多巴片允许更频繁的剂量,显著减少了血莱沃多巴波动. 这种方法为帕金森病患者提供了更安全,更一致的药物输送.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经学 神经学
- 药物输送系统 药物输送系统
背景情况:
- 列沃多巴/卡比多巴是帕金森病 (PD) 的首要治疗方法.
- 慢性脉动的勒沃多巴/卡比多巴给药会导致PD患者的运动并发症.
- 当前配方可能无法优化勒沃多巴血水平的一致性.
研究的目的:
- 为了评估一个新的,功能性得分的即时释放 (IR) 卡比多帕/莱沃多帕25/100毫克配方.
- 评估更频繁,更小剂量对勒沃多巴血变异性的影响.
- 为了比较不同剂量频率的安全性和耐受性.
主要方法:
- 第一阶段的研究涉及22名健康志愿者.
- 每4小时服用全片药片与每2小时服用半片药片的比较.
- 对新配方的生物等价性测试与标准IR片进行比较.
主要成果:
- 更频繁的剂量 (每2小时半片) 显著降低了44%的勒沃多巴血峰值.
- 利沃多巴水平的平均峰值-低谷差异和变异分别减少了51%和56%.
- 治疗方案之间对药物总体暴露或安全性/耐受性没有显著差异.
结论:
- 新的功能评分IR卡比多巴/莱沃多巴配方可使剂量更安全,更频繁.
- 这种剂量策略提供了更一致的勒沃多巴血水平,可能改善PD运动反应.
- 平板电脑技术可以增强PD患者的生理多巴胺补充,包括那些灵敏度问题.
相关概念视频
Parkinson's Disease: Treatment
273
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
273
Dosage Regimen: Fixed Dose
1.9K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.9K
Parkinson's Disease: Overview
553
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
553
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
150
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
150
Prodrugs
2.6K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
2.6K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
305
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
305


